S
Stefania Oliva
Researcher at University of Turin
Publications - 80
Citations - 3311
Stefania Oliva is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Minimal residual disease. The author has an hindex of 19, co-authored 72 publications receiving 2429 citations. Previous affiliations of Stefania Oliva include University of Siena.
Papers
More filters
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
TL;DR: This mini-review will focus on currently available techniques and data on MRD testing and their potential future applications.
Journal ArticleDOI
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Stefania Oliva,Maria Teresa Petrucci,Concetta Conticello,Lucio Catalano,Paolo Corradini,Agostina Siniscalchi,Valeria Magarotto,Luděk Pour,Angelo-Michele Carella,Alessandra Malfitano,Daniela Petro,Andrea Evangelista,Stefano Spada,Norbert Pescosta,Paola Omedè,Philip Campbell,Anna Marina Liberati,Massimo Offidani,Roberto Ria,Stefano Pulini,Francesca Patriarca,Roman Hájek,Andrew Spencer,Mario Boccadoro,Antonio Palumbo +24 more
TL;DR: In this article, the authors compared consolidation with high-dose melphalan plus autologous stem-cell transplantation (ASCT) versus chemotherapy (cyclophosphamide and dexamethasone) plus lenalidomide, and maintenance with lenalidmide plus prednisone versus lenalidmeide alone.
Journal ArticleDOI
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
Michele Cavo,Meral Beksac,Lucia Pantani,Maria Teresa Petrucci,Meletios A. Dimopoulos,Luca Dozza,Bronno van der Holt,Sonja Zweegman,Stefania Oliva,Vincent H.J. van der Velden,Elena Zamagni,Giuseppe A. Palumbo,Francesca Patriarca,Vittorio Montefusco,Monica Galli,Vladimir Maisnar,Barbara Gamberi,Markus Hansson,Angelo Belotti,Ludek Pour,Paula F. Ypma,Mariella Grasso,Alexsandra Croockewit,Stelvio Ballanti,Massimo Offidani,Iolanda Vincelli,Renato Zambello,Anna Marina Liberati,Niels Frost Andersen,Annemiek Broijl,Rossella Troia,Anna Pascarella,Giulia Benevolo,Mark-David Levin,Gerard M. J. Bos,Heinz Ludwig,Sara Aquino,Anna Maria Morelli,Ka Lung Wu,Rinske Boersma,Roman Hájek,Marc Durian,Peter A. von dem Borne,Tommaso Caravita di Toritto,Thilo Zander,Christoph Driessen,Giorgina Specchia,Anders Waage,Peter Gimsing,Ulf-Henrik Mellqvist,Marinus van Marwijk Kooy,Monique C. Minnema,Caroline Mandigers,Anna Maria Cafro,Angelo D. Palmas,Susanna Carvalho,Andrew Spencer,Mario Boccadoro,Pieter Sonneveld +58 more
TL;DR: Progressive progression-free survival was significantly improved with autologous HSCT compared with VMP and bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bORTezomIB-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
Journal ArticleDOI
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Ajai Chari,Mehmet Kemal Samur,Joaquin Martinez-Lopez,Gordon Cook,Noa Biran,Kwee Yong,Vania Hungria,Monika Engelhardt,Ana García Feria,Stefania Oliva,Rimke Oostvogels,Alessandro Gozzetti,Cara A. Rosenbaum,Shaji Kumar,Edward A. Stadtmauer,Hermann Einsele,Meral Beksac,Katja Weisel,Kenneth C. Anderson,Maria-Victoria Mateos,Philippe Moreau,Jesús F. San-Miguel,Nikhil C. Munshi,Nikhil C. Munshi,Hervé Avet-Loiseau +24 more
TL;DR: The baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society, are described to understand the initial challenges faced by myeloma patients during the CO VID-19 pandemic.